{
    "clinical_study": {
        "@rank": "109120", 
        "acronym": "Ghost-Basel", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Other", 
                "description": "Cortisol 20 mg /Placebo Mannitol"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Other", 
                "description": "Placebo Mannitol/Cortisol 20mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effects of cortisol on heroin craving and stress reaction in heroin\n      addicted subjects Randomized, double-blind, placebo-controlled, cross-over, single\n      administration of study medication Study hypothesis:Cortisol has an inhibiting effect on\n      heroin craving and stress reactivity in opioid dependent subjects."
        }, 
        "brief_title": "Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Opioid Dependence", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18\n\n          -  Opioid dependency\n\n          -  Participant in the Janus heroin programme of the UPK Basel\n\n          -  Able to control parallel consumption of other drugs\n\n          -  Stable i.v. substitution for at least 3 months\n\n        Exclusion Criteria:\n\n          -  co-morbid psychiatric disturbances\n\n          -  Current medical conditions excluding participation\n\n          -  Recent history of systemic or topic glucocorticoid therapy\n\n          -  known hypersensitivity to the IMP under investigation (cor-tisol)\n\n          -  pregnancy, breast-feeding\n\n          -  inability to read and understand the participant's information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718964", 
            "org_study_id": "2012DR2144"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "intervention_name": "Cortisol 20 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "Mannitol used as placebo", 
                "intervention_name": "Mannitol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate", 
                "Mannitol", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "4012"
                }, 
                "name": "Psychiatric Hospital"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acute Effects of Cortisol on Heroin Craving in Opioid Dependence", 
        "other_outcome": [
            {
                "description": "outcome measures will be taken during the participants 2 test visit days. Each participant will stay for approx. 3 hours.", 
                "measure": "Symptoms of withdrawal", 
                "safety_issue": "No", 
                "time_frame": "baseline, change from baseline during and after presentation of drug stimuli"
            }, 
            {
                "description": "outcome measures will be taken during the participants 2 test visit days. Each participant will stay for approx. 3 hours.", 
                "measure": "saliva cortisol level", 
                "safety_issue": "No", 
                "time_frame": "baseline, change from baseline during and after presentation of drug stimuli"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "outcome measures will be taken during the participants 2 test visit days. Each participant will stay for approx. 3 hours.", 
            "measure": "Heroin craving", 
            "safety_issue": "No", 
            "time_frame": "baseline, change from baseline during and after presentation of drug stimuli"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718964"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Basel", 
            "investigator_full_name": "Prof. Dominique de Quervain, MD", 
            "investigator_title": "Professor MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "outcome measures will be taken during the participants 2 test visit days. Each participant will stay for approx. 3 hours.", 
            "measure": "Anxiety", 
            "safety_issue": "No", 
            "time_frame": "baseline, change from baseline during and after presentation of drug stimuli"
        }, 
        "source": "University of Basel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prof. Dominique de Quervain, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}